ADC Therapeutics SA (NYSE: ADCT) has announced updated data from the LOTIS-7 Phase 1b open-label clinical trial, which evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The data will be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The trial results indicate a clinically meaningful benefit, with an overall response rate of 93.3% and a complete response rate of 86.7% among 30 evaluable patients. The combination treatment is generally well-tolerated, with a manageable safety profile, and the company is expanding the study enrollment to 100 patients at a 150 µg/kg dose. The data will also be shared at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. ADC Therapeutics will host a conference call to discuss these results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.